We have carried out extensive laboratory work to optimise a system to enhance the solubility of the crystals which cause gout (mono-sodium urate) in a model aqueous system using 'generally-regarded-as-safe' excipients. These results have enabled a full patent to be filed and we are looking to launch our first product in the very near future.
Completely novel approach targeting the actual cause of gout by increasing solubility of the mono-sodium urate crystals ‘in-vivo’ i.e. in the body
Can use non-invasive, safe ultrasound therapy to help the mono-sodium urate crystals to dissolve in-vivo
New formulation developed using already ''generally regarded as safe’ excipients delivered transdermally
Formulations comprise only previously tested and approved ingredients (excipients) which will avoid any animal testing for this new approach
